Currently available anticancer mAbs (e.g. Trastuzumab) recognize extracellular or cell surface proteins such as HER2, however, these proteins comprise only a small fraction of cellular proteins and are not completely tumor-specific. The gene discussed is ERBB2; the disease is neoplasm.